NUVL EBITDA
-$334.38MTTM · USD
Period ending:
NUVL FY EBITDAUSD
$20.38M-$126.22M
2019-12-312025-12-31
Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.
NUVL ebitda history
Earnings before interest, taxes, depreciation, and amortization. The available annual fiscal periods series contains 7 observations from Dec 31, 2019 to Dec 31, 2025.
| Period ending | EBITDA (USD) |
|---|---|
| -10,485,000 | |
| 20,376,000 | |
| -126,219,000 | |
| -81,854,000 | |
| -46,123,000 | |
| -16,905,000 | |
| -1,451,000 |
Compare ebitda
Other companies in Health Care. Each page shows its own reporting periods and currency.
- Guardant Health Inc (GH) ebitda
- Bridgebio Pharma Inc (BBIO) ebitda
- Brightspring Health Services Inc (BTSG) ebitda
- Madrigal Pharmaceuticals Inc (MDGL) ebitda
- Ensign Group Inc (ENSG) ebitda
- Glaukos Corp (GKOS) ebitda
- Vaxcyte Inc (PCVX) ebitda
- Krystal Biotech Inc (KRYS) ebitda
All NUVL financial metrics · NUVL stock overview · How to interpret financial metrics
